Immunic Press Release
2020-08-20

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Immunic, Inc. Announces Dosing of…
read more
Immunic Press Release
2020-08-20

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunic, Inc. Announces Closing of…
read more
Immunic Press Release
2020-08-20

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Immunic, Inc. Announces Pricing of…
read more
Immunic Press Release
2020-06-15

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Immunic, Inc. Announces First Patients…
read more
Immunic Press Release
2020-06-12

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

Immunic, Inc. Announces Pricing of…
read more
Immunic Press Release
2020-05-14

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

Immunic, Inc. Receives First Regulatory…
read more
Immunic Press Release
2020-04-24

Immunic, Inc. Announces Pricing of $15 Million Financing

Immunic, Inc. Announces Pricing of…
read more
Immunic Press Release
2020-04-22

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

Immunic, Inc. Reports that IMU-838,…
read more
Immunic Press Release
2019-10-16

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

Immunic, Inc. Expands Board of…
read more
Immunic Press Release
2019-10-11

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Immunic, Inc. Announces Completion of…
read more